cisapride has been researched along with Birth Weight in 3 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this prospective multicenter study was to determine whether cisapride is associated with increased risk of malformations, spontaneous abortions, or decreased birthweight when used during pregnancy." | 7.69 | Cisapride use during human pregnancy: a prospective, controlled multicenter study. ( Addis, A; Bailey, B; Bonati, M; Conover, B; De Souza, CF; Garbis, H; Koren, G; Lau, M; Lee, A; Mastroiacovo, P; Matsui, D; Mazzone, T; Paolini, C; Sanghvi, K; Schechtman, AS; Val, T, 1997) |
| " No significant correlation was found between birth weight or gestational age and the change in QTc values during Cisapride treatment in the appropriate for gestational age group." | 5.11 | Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants. ( Capretti, MG; Corvaglia, L; Faldella, G; Lanari, M; Rotatori, R; Salvioli, GP, 2004) |
| "The objective of this prospective multicenter study was to determine whether cisapride is associated with increased risk of malformations, spontaneous abortions, or decreased birthweight when used during pregnancy." | 3.69 | Cisapride use during human pregnancy: a prospective, controlled multicenter study. ( Addis, A; Bailey, B; Bonati, M; Conover, B; De Souza, CF; Garbis, H; Koren, G; Lau, M; Lee, A; Mastroiacovo, P; Matsui, D; Mazzone, T; Paolini, C; Sanghvi, K; Schechtman, AS; Val, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corvaglia, L | 1 |
| Faldella, G | 1 |
| Rotatori, R | 1 |
| Lanari, M | 1 |
| Capretti, MG | 1 |
| Salvioli, GP | 1 |
| Kohl, M | 1 |
| Wuerdemann, I | 1 |
| Clemen, J | 1 |
| Iven, H | 1 |
| Katalinic, A | 1 |
| Moeller, JC | 1 |
| Bailey, B | 1 |
| Addis, A | 1 |
| Lee, A | 1 |
| Sanghvi, K | 1 |
| Mastroiacovo, P | 1 |
| Mazzone, T | 1 |
| Bonati, M | 1 |
| Paolini, C | 1 |
| Garbis, H | 1 |
| Val, T | 1 |
| De Souza, CF | 1 |
| Matsui, D | 1 |
| Schechtman, AS | 1 |
| Conover, B | 1 |
| Lau, M | 1 |
| Koren, G | 1 |
2 trials available for cisapride and Birth Weight
| Article | Year |
|---|---|
Intrauterine growth retardation is a risk factor for cisapride-induced QT prolongation in preterm infants.
Topics: Anti-Ulcer Agents; Birth Weight; Cisapride; Electrocardiography; Female; Fetal Growth Retardation; H | 2004 |
Cisapride may improve feeding tolerance of preterm infants: a randomized placebo-controlled trial.
Topics: Birth Weight; Cisapride; Digestive System Diseases; Electrocardiography; Enteral Nutrition; Female; | 2005 |
1 other study available for cisapride and Birth Weight
| Article | Year |
|---|---|
Cisapride use during human pregnancy: a prospective, controlled multicenter study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Birth Weight; Case-Control Studies; Cisap | 1997 |